Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959423 | 0.87 | LMNA (0.44) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL2951453 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL2959759 | 0.87 | LMNA (0.48) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL2953456 | 0.85 | HPGD (0.45) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL2953765 | 0.84 | KDM4E (0.46) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2958478 | 0.83 | NPSR1 (0.43) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL5635601 | 0.79 | MAPT (0.42) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL5635038 | 0.76 | LMNA (0.48) | ALDH1A1KMT2AMEN1NPSR1MAPT | |
| SCHEMBL5635225 | 0.75 | MAPT (0.37) | NPSR1MAPT | |
| SCHEMBL2950804 | 0.74 | MAPT (0.36) | ALDH1A1MAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763643-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7488746-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20080070947-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-7317033-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20060160873-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-7049333-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-23 | — | — | US | disclosed |
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | PLAT, CPS1, TST | ALDH1A1 429/4885KMT2A 3784/4885MEN1 4291/4885 |
| US-20040006119-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | TST, GOT2, ALPP | ALDH1A1 386/4885KMT2A 3747/4885MEN1 4107/4885 |
| US-20080070947-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | PLAT, TST, PNLIP | ALDH1A1 400/4885KMT2A 3668/4885MEN1 4233/4885 |
| US-20060160873-A1 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | PLAT, TST, PNLIP | ALDH1A1 400/4885KMT2A 3668/4885MEN1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.